MAR-001 is under clinical development by Marea Therapeutics and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs for Hypertriglyceridemia have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MAR-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MAR-001 overview
MAR-001 is under development for the treatment of hypertriglyceridemia. The therapeutic candidate is administered through subcutaneous route.
Marea Therapeutics overview
Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules for the treatment of autoimmune and inflammatory diseases in the fields of cardiology, blood related diseases and offers other services. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MAR-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
